| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
In nephroblastoma, identification of new prognostic markers for better therapy planning are needed to improve the mortality and recurrence rate, and prevent side and late effects. We previously showed that WTX abnormality in nephroplastoma were correlated with poor prognosis in Japanese nephroplastoma. Some of nephroblastoma patients are long-term survive without relapse. In nephroblastoma with WTX abnormality, we performed SNP array analysis to clarify chromosomal abnormalities correlated with cancer death in 27 nephroblastoma with WTX abnormality. We couldn't identify chromosomal abnormalities correlated specifically with cancer death or event free. We have been performing comprehensive gene expression analysis for identification of signal pathway correlated with therapy resistance in nephroblastoma with WTX abnormality.
|
